Targeted Oncology3h
Gasparetto Explains Rationale for Quadruplet Front Line in Transplant-Ineligible Myeloma
In a Community Case Forum in partnership with the North Carolina Oncology Association, Cristina Gasparetto, MD, discussed the ...
Targeted Oncology17h
Fedratinib Shows Safety, Potential as Post-Transplant Therapy in MPNs
Hany Elmariah, MD, discussed the safety profile of fedratinib and its evolving role in the post-transplant setting for patients with myeloproliferative neoplasms.
Targeted Oncology19h
Updated Findings on Datopotamab Deruxtecan in Urothelial Cancer Treatment
Bernstam, MD, discusses updated findings from the phase 1 TROPION-PanTumor01 study of datopotamab deruxtecan-dlnk in heavily ...
Targeted Oncology21h
FDA Grants Fast Track Designation to 67Cu-SAR-bisPSMA in mCRPC
The FDA has granted fast track status to 67Cu-SAR-bisPSMA for metastatic prostate cancer that is resistant to hormone therapy ...